Clinical Trials

Filter by condition

Filter by location

  1. Rochester, MN. (3)

3 studies in Division of Cardiovascular Diseases

  1. Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
    Rochester, Minn. View Summary

    Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients

    Location:

    Rochester, Minn.

    Trial status:

    Open for Enrollment

    Why is this study being done?

    The purpose of this study is to determine whether allopurinol is effective in relieving symptoms of patients with heart failure and high blood uric acid levels.

    NCT ID:

    NCT00987415

    Who can I contact for additional information about this study?

    Rochester: Margaret Redfield, MD
                        


  2. Establishment of Normal Ranges for Newly Developed Cardiovascular Assays
    Rochester, Minn. View Summary

    Establishment of Normal Ranges for Newly Developed Cardiovascular Assays

    Location:

    Rochester, Minn.

    Trial status:

    Open for Enrollment

    Why is this study being done?

    This research study is being done to determine levels of proteins that are normally present in the blood and urine of healthy individuals so as to compare to those levels in patients with heart disease.

    Normal blood and urine will be analyzed for levels of proteins and cardiac peptides which are affected by heart disease in the elderly. We are trying to determine if there are normal age-related changes when heart disease is not involved.

    IRB Number:

    718-05

    Who can I contact for additional information about this study?

    If you are interested in participating in this study or would like additional information, please contact Sharon Sandberg or Dr. Fernando Martin at (507) 284-4838.
  3. Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients
    Rochester, Minn. View Summary

    Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients

    Location:

    Rochester, Minn.

    Trial status:

    Open for Enrollment

    Why is this study being done?

    The HeartMate II (HM II) LVAD is approved by the U.S. Food and Drug Administration (FDA) for use in destination therapy (DT) patients with New York Heart Association (NYHA) Class IIIB/IV symptoms. The ROADMAP trial is a prospective, multi-center, non-randomized, controlled, observational study that is designed to evaluate the effectiveness of HM II LVAD support versus optimal medical management (OMM) in ambulatory NYHA Class IIIB/IV heart failure patients who are not dependent on intravenous inotropic support and who meet the FDA approved indications for HM II LVAD destination therapy. Subjects will be enrolled in one of two cohorts: OMM or LVAD. Together with the investigator, the subjects will decide which cohort to enter into at their baseline visit. This study will include experienced HM II LVAD implant centers as well as community centers that care for a large volume of heart failure patients. Study patients will be followed for up to 24 months post enrollment for survival, quality of life and functional status.

    NCT ID:

    NCT01452802

    Who can I contact for additional information about this study?

    Rochester: Cathy Severson